Table 1.
Baseline patient demographics.
| Patient characteristics | |
|---|---|
| Number of patients evaluable/enrolled | 54/55 |
| Median age, years (range) | 51 (27–81) |
| ECOG performance status | |
| 0 | 16 |
| 1 | 38 |
| Unknown | 1 |
| Sex | |
| Male | 24 |
| Female | 31 |
| Diagnosis | |
| Leiomyosarcoma, total (uterine; nonuterine) | 11 (8; 3) |
| Alveolar soft-part sarcoma | 8 |
| Undifferentiated pleomorphic sarcoma | 5 |
| Synovial sarcoma | 4 |
| Myxofibrosarcoma, total (standard; fibrosarcoma variant) | 4 (3; 1) |
| Clear cell sarcoma | 3 |
| Spindle cell sarcoma | 3 |
| Extraskeletal myxoid chondrosarcoma | 3 |
| Liposarcoma, total (myxoid; well differentiated/dedifferentiated) | 3 (2; 1) |
| Endometrial spindle sarcoma | 2 |
| MPNST | 2 |
| Embryonal rhabdomyosarcoma | 2 |
| PNET | 1 |
| Myofibroblastic sarcoma | 1 |
| Malignant myoepithelioma | 1 |
| Solitary fibrous tumor | 1 |
| GIST | 1 |
| Prior lines of therapy | |
| Nonea | 3 |
| 1 | 11 |
| ≥2 | 41 |
| Median (range) | 2 (0–8) |
| Doxorubicin/liposomal doxorubicin-based therapy | 30 |
| Anti-VEGF therapy/TKI therapy | 19 |
| Immunotherapy | 10 |
| Checkpoint inhibitor (single or double inhibitor) | 6 |
| Other (interferon alpha or vaccine) | 4 |
aNo standard therapy option available.